A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 383 participants.
Also called NCT05048719
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 383 participants
- Sponsor
- Registry
-
NCT05048719 -
2021-002806-29
-
- Other papers using this trial's data
- Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Hungary, Poland, Puerto Rico, Slovakia
- Registry status
- Completed
Technical summary
Registry record NCT05048719. Randomized; double masking; primary purpose treatment. Start 2021-09-15 (actual); primary completion 2022-09-30 (actual). Results posted on 2023-10-17.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- LY3502970
- Intervention (Drug)
- Dulaglutide
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Placebo
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct05048719- Content hash
663b3cd2b1eae67955bcdf4d7a8fa94b11becbb94863147ea90b10283fd9b3e6